Duchenne Muscular Dystrophy Clinical Trial
Official title:
Investigation Of Factors Affecting Hand Functions in Nonambulatory Patients With Duchenne Muscular Dystrophy
The aim of this study, determining the factors affecting the hand functions of children with Duchenne Muscular Dystrophy who have lost their independent ambulatory ability and determining the effects on the overall upper extremity performance and quality of life of the determined factors.
Duchenne Muscular Dystrophy (DMD) is the most common neuromuscular disease seen in childhood.
DMD is an X linked recessive disorder. DMD is characterized by complete or partial (<3%)
deficiency of the cell membrane protein dystrophin.
Dystrophin deficiency results in a permanent deterioration of muscle fibers. This leads to a
progressive decrease in muscle strength and functional abilities. The precise mechanism of
how the defect of dystrophin leads to degeneration of muscle fibers remains uncertain, but
cytoskeletal deterioration, sarcolemmal instability and abnormal calcium homeostasis are
thought to play a role in this degeneration.
These patients have symptoms such as limb proximals and progressive muscle weakness in the
trunk, gait abnormalities, Gower's sign, various degrees of restriction in daily living
activities, and frequent falls. The majority of patients have elevated serum creatine kinase
or elevated liver transaminases and less frequently language or general developmental
retardation.
Walking ability of this children begins to deteriorate between the ages of 3-6. These
patients are generally dependent on wheelchair aged 10-12 years. The loss of walking is the
milestone in terms of the progression of the disease. The use of electric wheelchairs limits
arm functions such as lengthening and lifting during the late phase of the illness (when the
ambulance has been lost and the ambulance is being continued with the wheelchair).
Patients with DMD have an average life span of 30 years with spinal surgery and ventilation
support. They spend most of their lives dependent on the wheelchair and need functional use
of the upper limbs to maintain the best possible level of independence in their daily life
activities throughout their lifetimes.
Although muscle weakness in the proximal limbs is the first finding of the disease, the
influence of upper extremity functions gives symptoms after 8 years of age and has a great
influence on the level of independence of DMD patients in life since this process. For this
reason, rehabilitation approaches for the protection of upper extremity functions from the
early period of the disease are of great importance.Effective interventions are necessary to
achieve this goal and these variables must be considered when making clinical decisions.
Patients with adult DMD have been shown to be able to perform important functional activities
with limited distal motor function in the late phase of disease, but tend to lose these
capacities as muscle strength decreases. For this reason, determining the factors (grip
strength, thumb opposition, upper extremity joint range of motion, upper extremity muscle
strength, etc.) that may affect hand functions, which is an important component in
maintaining upper extremity functioning, and how these factors are related to the general
functions of the upper extremity it is crucial that this disease leads to physiotherapy
rehabilitation programs to be implemented.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05575648 -
Dual Task in Duchenne Muscular Dystrophy
|
N/A | |
Terminated |
NCT03907072 -
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06450639 -
An Open-label Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT04335942 -
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor
|
N/A | |
Active, not recruiting |
NCT04906460 -
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02500381 -
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
|
Phase 3 | |
Enrolling by invitation |
NCT05967351 -
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
|
Phase 3 | |
Recruiting |
NCT03067831 -
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Recruiting |
NCT01834040 -
Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy
|
Phase 1/Phase 2 | |
Completed |
NCT02246478 -
A Study of TAS-205 for Duchenne Muscular Dystrophy
|
Phase 1 | |
Active, not recruiting |
NCT01772043 -
Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping
|
N/A | |
Terminated |
NCT01168908 -
Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy
|
Phase 2 | |
Completed |
NCT00758225 -
Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)
|
Phase 2 | |
Completed |
NCT03680365 -
Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
|
||
Recruiting |
NCT03513367 -
The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory :PedsQLTM.
|
||
Recruiting |
NCT05712447 -
Duchenne Muscular Dystrophy Video Assessment Registry
|
||
Recruiting |
NCT01484678 -
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
|
||
Completed |
NCT03319030 -
Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)
|
||
Terminated |
NCT01753804 -
A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.
|
N/A | |
Completed |
NCT02530905 -
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
|
Phase 1 |